File Download

There are no files associated with this item.

Supplementary

Conference Paper: Safety, tolerability, pharmacokinetics and antiviral activity of AL-3778, a first-in-class, HBV core assembly modulator alone and in combination with peginterferon-alpha 2A, in treatment naive HBeAg-positive chronic hepatitis B patients

TitleSafety, tolerability, pharmacokinetics and antiviral activity of AL-3778, a first-in-class, HBV core assembly modulator alone and in combination with peginterferon-alpha 2A, in treatment naive HBeAg-positive chronic hepatitis B patients
Authors
Issue Date2017
Citation
26th Annual Conference of APASL, February 15–19, 2017, Shanghai, China. Hepatology International, v. 11 n. Suppl 1, p. S7 How to Cite?
Persistent Identifierhttp://hdl.handle.net/10722/245570

 

DC FieldValueLanguage
dc.contributor.authorKennedy, W-
dc.contributor.authorYuen, RMF-
dc.contributor.authorKim, DJ-
dc.contributor.authorWeilert, F-
dc.contributor.authorChan, HLY-
dc.contributor.authorLalezari, J-
dc.contributor.authorHwang, SG-
dc.contributor.authorNguyen, T-
dc.contributor.authorWestland, C-
dc.contributor.authorKakuda, T-
dc.contributor.authorBrown, N-
dc.contributor.authorKlumpp, K-
dc.contributor.authorFlores, L-
dc.contributor.authorTalloen, W-
dc.contributor.authorLenz, O-
dc.contributor.authorGane, E-
dc.contributor.authorvan Remoortere, P-
dc.contributor.authorChandra, S-
dc.contributor.authorFry, J-
dc.date.accessioned2017-09-18T02:13:01Z-
dc.date.available2017-09-18T02:13:01Z-
dc.date.issued2017-
dc.identifier.citation26th Annual Conference of APASL, February 15–19, 2017, Shanghai, China. Hepatology International, v. 11 n. Suppl 1, p. S7-
dc.identifier.urihttp://hdl.handle.net/10722/245570-
dc.languageeng-
dc.relation.ispartof26th Annual Conference of APASL, February 15–19, 2017, Shanghai, China. Hepatology International-
dc.titleSafety, tolerability, pharmacokinetics and antiviral activity of AL-3778, a first-in-class, HBV core assembly modulator alone and in combination with peginterferon-alpha 2A, in treatment naive HBeAg-positive chronic hepatitis B patients-
dc.typeConference_Paper-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.authorityYuen, RMF=rp00479-
dc.identifier.hkuros278503-
dc.identifier.volume11-
dc.identifier.issueSuppl 1-
dc.identifier.spageS7-
dc.identifier.epageS7-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats